Paper · 41513808
K5 polysaccharides inhibit SARS-CoV-2 infection by preventing spike-proteolytic priming.
Milanesi M and 11 others. Npj Viruses, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. K5 polysaccharides inhibit SARS-CoV-2 infection by preventing spike-proteolytic priming. Papers, record 41513808. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41513808
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CUP B53C22001820006 | European Union (NextGenerationEU), Italian NRRP project code IR0000031 - Strengthening BBMRI.it | PubMed | ||
| TTU 04.710 | Deutsches Zentrum für Infektionsforschung (DZIF) | PubMed | ||
| ExU 6.1.20 (CoVLP) | Heidelberg University Flagship Initiative in "Engineering Molecular Systems" | PubMed | ||
| ExU 6.1.20 (CoVLP) | Heidelberg University Flagship Initiative in "Engineering Molecular Systems" | PubMed | ||
| 458623378 | Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) | PubMed | ||
| 458623378 | Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) | PubMed | ||
| INST 35/1134-1 FUGG | German Research Foundation (DFG) | PubMed | ||
| INST 35/1134-1 FUGG | German Research Foundation (DFG) | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33,493,182 | Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion. | PLoS Pathog | 2021 | https://conductscience.org/library/papers/33493182 | PubMed |
| 2 | 35,104,837 | Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. | Nature | 2022 | https://conductscience.org/library/papers/35104837 | PubMed |
| 3 | 38,205,179 | A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety. | Infect Med (Beijing) | 2023 | https://conductscience.org/library/papers/38205179 | PubMed |
| 4 | 34,929,169 | The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms. | J Biol Chem | 2022 | https://conductscience.org/library/papers/34929169 | PubMed |
| 5 | 34,951,565 | SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. | Emerg Microbes Infect | 2022 | https://conductscience.org/library/papers/34951565 | PubMed |
| 6 | 35,106,370 | GlycoGrip: Cell Surface-Inspired Universal Sensor for Betacoronaviruses. | ACS Cent Sci | 2022 | https://conductscience.org/library/papers/35106370 | PubMed |
| 7 | 33,668,969 | Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/33668969 | PubMed |
| 8 | 32,057,769 | The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. | Antiviral Res | 2020 | https://conductscience.org/library/papers/32057769 | PubMed |
| 9 | 32,132,184 | Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. | Science | 2020 | https://conductscience.org/library/papers/32132184 | PubMed |
| 10 | 35,691,607 | Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. | J Pharm Sci | 2022 | https://conductscience.org/library/papers/35691607 | PubMed |
1 to 10 of 62
See all 62 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ACE2 | 59,272 | PubTator's text mining | https://conductscience.org/library/genes/59272 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41513808
GET https://conductscience.org/api/papers/v1/41513808/references?page=2